Immunology Investor Event

sanofi Dupixent: Chronic Rhinosinusitis with Nasal Polyposis Prevalence(1) Number of patients (thousands) Treated 227 Moderate-to-Severe 484 407 147 191 147 485 Biologics eligible 90 74 43 207 423 214 848 907 Inadequately controlled CRSWNP(3) Most in need 55 47 16 118 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 800 850 900 950 Patients uncontrolled despite prior surgery US Europe (2) Japan Source: Sanofi analysis (1) 18+ population (2) Germany, France, Italy, Spain & United Kingdom (3) For Europe, patients with severe CRSWNP inadequately controlled on systemic corticosteroids and / or surgery 9 Immunology Investor Event

View entire presentation